NASDAQ:ITCI - Intra-Cellular Therapies Stock Price, Forecast & News

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies Inc (NASDAQ:ITCI) released its earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, beating analysts' consensus estimates of ($0.80) by $0.17. View Intra-Cellular Therapies' Earnings History.

Intra-Cellular Therapies is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Intra-Cellular Therapies.

8 brokerages have issued 12-month price objectives for Intra-Cellular Therapies' stock. Their forecasts range from $16.00 to $73.00. On average, they anticipate Intra-Cellular Therapies' stock price to reach $36.57 in the next year. This suggests a possible upside of 39.3% from the stock's current price. View Analyst Price Targets for Intra-Cellular Therapies.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intra-Cellular Therapies.

Headlines about ITCI stock have trended positive on Saturday, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Intra-Cellular Therapies earned a media sentiment score of 2.4 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an effect on the stock's share price in the near term. View News Stories for Intra-Cellular Therapies.

Intra-Cellular Therapies saw a drop in short interest in the month of December. As of December 31st, there was short interest totalling 8,370,000 shares, a drop of 34.9% from the December 15th total of 12,850,000 shares. Based on an average daily trading volume, of 2,640,000 shares, the days-to-cover ratio is presently 3.2 days. Approximately 17.9% of the company's shares are short sold. View Intra-Cellular Therapies' Current Options Chain.

Some companies that are related to Intra-Cellular Therapies include Arrowhead Pharmaceuticals (ARWR), Global Blood Therapeutics (GBT), BridgeBio Pharma (BBIO), United Therapeutics (UTHR), Allakos (ALLK), SAGE Therapeutics (SAGE), Nektar Therapeutics (NKTR), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), FibroGen (FGEN), Mirati Therapeutics (MRTX), Evotec (EVTCY), GW Pharmaceuticals PLC- (GWPH), Deciphera Pharmaceuticals (DCPH) and Intercept Pharmaceuticals (ICPT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Synergy Pharmaceuticals (SGYP), Amarin (AMRN), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), GW Pharmaceuticals PLC- (GWPH), Intercept Pharmaceuticals (ICPT), Zynerba Pharmaceuticals (ZYNE), Myovant Sciences (MYOV), Crispr Therapeutics (CRSP) and Gilead Sciences (GILD).

Intra-Cellular Therapies' stock is owned by a number of of institutional and retail investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.90%), Assenagon Asset Management S.A. (0.03%), Gainplan LLC (0.02%) and Kistler Tiffany Companies LLC (0.00%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Joel S Marcus, Kimberly E Vanover, Lawrence J Hineline, Mark Neumann, Michael Halstead, Robert E Davis and Sharon Mates. View Institutional Ownership Trends for Intra-Cellular Therapies.

ITCI stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Andrew Satlin, Lawrence J Hineline, Mark Neumann, Michael Halstead and Sharon Mates. View Insider Buying and Selling for Intra-Cellular Therapies.

ITCI stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Gainplan LLC and Kistler Tiffany Companies LLC. View Insider Buying and Selling for Intra-Cellular Therapies.

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ITCI stock can currently be purchased for approximately $26.25.

Intra-Cellular Therapies has a market capitalization of $1.45 billion and generates $250,000.00 in revenue each year. The biopharmaceutical company earns $-155,130,000.00 in net income (profit) each year or ($2.84) on an earnings per share basis. Intra-Cellular Therapies employs 73 workers across the globe.View Additional Information About Intra-Cellular Therapies.

The official website for Intra-Cellular Therapies is http://www.intracellulartherapies.com/.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 646-440-9333 or via email at [email protected]